Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.61 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16190249 | 0.91 | TRPV1 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL15206243 | 0.90 | TRPV1 (0.62) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL6675668 | 0.86 | CHRM1 (0.65) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL6069869 | 0.86 | CHRM1 (0.65) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL12613755 | 0.86 | CHRM1 (0.65) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL2239855 | 0.86 | CA4 (0.58) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL24045921 | 0.85 | TRPV1 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL12501502 | 0.85 | CHRM1 (0.63) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL12613829 | 0.85 | CHRM1 (0.63) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL3817985 | 0.84 | APP (0.63) | CHRM1PDE4ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3778 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250128055-A1 | TREATMENT OF PSYCHIATRIC DISORDERS WITH DEEP BRAIN STIMULATION | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2025-04-24 | — | — | US | claimed |
| EP-4392125-A1 | TREATMENT OF PSYCHIATRIC DISORDERS WITH DEEP BRAIN STIMULATION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-07-03 | — | — | EP | claimed |
| CN-117462509-A | Enteric soft gelatin capsule | R·P·谢勒技术有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| WO-2023057977-A1 | TREATMENT OF PSYCHIATRIC DISORDERS WITH DEEP BRAIN STIMULATION | ALBERT LUDWIGS UNIVERSITÄT FREIBURG (DE) | 2023-04-13 | — | — | WO | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| US-20020081333-A1 | Orally administrable opioid formulations having extended duration of effect | PURDUE PHARMA L.P. | 2002-06-27 | — | — | US | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| US-6294195-B1 | BIOAVAILABLE SUSTAINED-RELEASE; HYDROPHOBIC MATERIAL SELECTED FROM THE GROUP CONSISTING OF AN ALKYLCELLULOSE, AN ACRYLIC RESIN AND MIXTURES THEREOF, SAID MATRICES FURTHER COMPRISING AT LEAST ONE C12-C36 ALIPHATIC ALCOHOL | PURDUE PHARMA L.P. | 2001-09-25 | — | — | US | claimed |
| US-6290638-B1 | Electromagnetic method of treatment of epilepsy and apparatus therefor | CANEDO LUIS E (MX) | 2001-09-18 | — | — | US | claimed |
| US-6027908-A | DIAGNOSING PREMATURE DELIVERY BY MEASURING INTERLEUKIN-8 (IL-8) LEVELS IN VAGINAL SECRETORY FLUID OR CERVICAL MUCUS; CORRELATING IL-8 LEVELS ABOVE A GIVEN CONCENTRATION WITH POSSIBILITY OF PREMATURE DELIVERY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2000-02-22 | — | — | US | claimed |
| US-5968551-A | SUSTAINED RELEASE ANALGESICS; BIOAVAILIBILITY | PURDUE PHARMA L.P. (US) | 1999-10-19 | — | — | US | claimed |
| EP-0754946-A1 | METHOD OF DISCRIMINATING VAGINAL SECRETION OR CERVICAL MUCUS OF GRAVIDA SUSPECTED OF THREATENED PREMATURE DELIVERY | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1997-01-22 | — | — | EP | claimed |
| WO-1996013226-A1 | METHOD FOR THE TREATMENT OF PERIODONTAL DISEASE AND A PHARMACEUTICAL COMPOSITION USEFUL IN SAID METHOD | SEPRACOR INC. (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| US-4066075-A | U-shape intravaginal device | THE PROCTER & GAMBLE COMPANY (US) | 1978-01-03 | — | — | US | claimed |